Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery.
OBJECTIVE
To evaluate long-term effects of operative hysteroscopy on the development of intrauterine adhesions (IUA), and to determine whether hypoestrogenism has a modulatory role in preventing IUA.


METHODS
Prospective, randomized study (Canadian Task Force classification I).


METHODS
Tertiary-care teaching hospital.


METHODS
Ninety-five women requiring resectoscopic surgery. Intervention. Hysteroscopic surgery using the resectoscope and 1.5% glycine for uterine distention.


RESULTS
Indications for hysteroscopy were polyps (28 patients), solitary myoma (32), multiple myomata (20), and uterine septa (15). Patients in each group were randomized to endometrial suppression with danazol or placebo. Second-look office hysteroscopy with CO2 for uterine distention was performed after the first menses after surgery to assess the frequency, extent, and severity of IUA. The likelihood and severity of IUA depended on the pathology treated at initial surgery. Of women treated for polyps and uterine septa, in only one with septa (placebo group) developed IUA. Mild IUA formation was present in 10 patients (31.3%) with solitary fibroids and 9 (45.5%) with multiple myomata. The frequency was similar in placebo- and danazol-treated groups with both solitary and multiple myomas (50% and 44.4% vs 50% and 55.6%). All IUA were lysed during second-look surgery, except in one woman with multiple myomata who required repeat resectoscopy.


CONCLUSIONS
Intrauterine adhesions are the major long-term complication of operative hysteroscopy, with frequency dependent on the pathology initially treated. Second-look office hysteroscopy is a cost-effective method of diagnosing and lysing IUA after resectoscopy.
Department of Obstetrics and Gynecology, Akdeniz University Medical School, Antalya, Turkey.
O
O
Taskin
S
S
Sadik
A
A
Onoglu
R
R
Gokdeniz
E
E
Erturan
F
F
Burak
J M
JM
Wheeler
D000328:Adult; D003613:Danazol / Q000627:therapeutic use*; D004564:Electrocoagulation; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015907:Hysteroscopy / Q000009:adverse effects*; D011446:Prospective Studies; D000267:Tissue Adhesions / Q000517:prevention & control; D014591:Uterine Diseases / Q000517:prevention & control*
D004965:Estrogen Antagonists; D003613:Danazol